在接受 mRNA-1273 疫苗接种者的血浆中检测到循环严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗抗原。
Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
机构信息
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.
出版信息
Clin Infect Dis. 2022 Mar 1;74(4):715-718. doi: 10.1093/cid/ciab465.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).
摘要
对 13 名接受两剂 mRNA-1273 疫苗的参与者的纵向血浆样本进行了严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）蛋白检测。在首次疫苗注射后 1 天，13 名参与者中有 11 名就已经检测到 SARS-CoV-2 蛋白。可检测到的 SARS-CoV-2 蛋白的清除与免疫球蛋白 G（IgG）和免疫球蛋白 A（IgA）的产生相关。
相似文献
1
Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
Clin Infect Dis. 2022 Mar 1;74(4):715-718. doi: 10.1093/cid/ciab465.
2
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
3
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.
4
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
5
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.
6
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
7
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Front Immunol. 2021 Oct 12;12:744887. doi: 10.3389/fimmu.2021.744887. eCollection 2021.
8
Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination.
Virus Res. 2024 Jan 2;339:199294. doi: 10.1016/j.virusres.2023.199294. Epub 2023 Dec 6.
9
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
10
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Vaccine. 2022 Mar 18;40(13):2044-2052. doi: 10.1016/j.vaccine.2022.02.030. Epub 2022 Feb 8.
引用本文的文献
1
Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways?
Int J Mol Sci. 2025 Aug 15;26(16):7879. doi: 10.3390/ijms26167879.
2
Vaxtherapy, a Multiphase Therapeutic Protocol Approach for Longvax, the COVID-19 Vaccine-Induced Disease: Spike Persistence as the Core Culprit and Its Downstream Effects.
Diseases. 2025 Jun 30;13(7):204. doi: 10.3390/diseases13070204.
3
The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury.
Adv Virol. 2025 Jun 24;2025:7990876. doi: 10.1155/av/7990876. eCollection 2025.
4
Soluble SARS-CoV-2 Spike glycoprotein: considering some potential pathogenic effects.
Front Immunol. 2025 Jun 4;16:1616106. doi: 10.3389/fimmu.2025.1616106. eCollection 2025.
5
Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database.
Eur J Clin Pharmacol. 2025 Jun 6. doi: 10.1007/s00228-025-03854-2.
6
A Multiscale Quantitative Systems Pharmacology Model for the Development and Optimization of mRNA Vaccines.
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1213-1224. doi: 10.1002/psp4.70041. Epub 2025 May 26.
7
mRNA-1273 is placenta-permeable and immunogenic in the fetus.
Mol Ther Nucleic Acids. 2025 Feb 17;36(1):102489. doi: 10.1016/j.omtn.2025.102489. eCollection 2025 Mar 11.
8
Blood donor SARS-CoV-2 infection or vaccination and adverse outcomes in plasma and platelet transfusion recipients.
Transfusion. 2025 Mar;65(3):485-495. doi: 10.1111/trf.18159. Epub 2025 Feb 26.
9
Complex Pattern of Platelet Activation/Reactivity After SARS-CoV-2 Infection.
Int J Mol Sci. 2024 Dec 24;26(1):49. doi: 10.3390/ijms26010049.
10
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.
Curr Top Med Chem. 2025;25(12):1467-1491. doi: 10.2174/0115680266325847241121034100.
Zotero 插件